血脂异常人群基因多态性对药物应用的意义

The Significance of Gene Polymorphism in DyslipidemiaPopulation for Medication Usage Application

目的通过分析在健康体检中发现的血脂异常人群及其ApoE、SLCO1B1及CYP2C19基因多态性分布情况,以便为他汀类药物及氯吡格雷的临床使用提供参考。方法使用全自动生化仪对2021年10月到我院进行体检的部分人群的总胆固醇(TC)、三酰甘油(TG)项目进行检测,按照检测结果对血脂异常情况进行分类。同时使用荧光PCR法进行ApoE、SLCO1B1、CYP2C19基因的多态性检测,分析基因多态性分布情况。结果202例血脂异常体检者ApoE基因表型中77.73%为E2型和E3型;22.28%为E4型。SLCO1B1基因表型中80.20%为Ⅰ类野生型,1.49%为Ⅲ类纯合突变型。CYP2C19基因表型中41.09%为EM型;24.26%为PM型。结论对202例血脂异常体检者ApoE、SLCO1B1和CYP2C19基因多态性的分布进行分析,获得该人群个体化用药信息,为个体化用药提供数据支持,对实现个体化精准与安全用药具有指导意义。

Objective To provide reference for the clinical use of statins and clopidogrel by analyzing the distribution of ApoE,SLCO1B1 and CYP2C19 gene polymorphisms of dyslipidemia found in people during physical examinations.Methods Total cholesterol(TC)and triglyceride(TG)of the people who underwent physical examination in our hospital in October 2021 were tested by automatic biochemical analyzer,and abnormal blood lipids were classified according to the results.At the same time,the polymorphisms of ApoE,SLCO1B1 and CYP2C19 genes were tested by fluorescence PCR,and the polymorphism distribution of those genes was analyzed.Results In 202 cases of dyslipidemia,77.73%of ApoE gene phenotypes were E2 and E3,and 22.28%of ApoE gene phenotypes of were E4.80.20%of SLCO1B1 gene phenotypes were typeⅠwild type,while 1.49%of SLCO1B1 gene phenotypes were typeⅢhomozygous mutant type.41.09%of CYP2C19 gene phenotypes were EM type,and 24.26%of CYP2C19 gene phenotypes were PM type.Conclusion In this study,the distribution of ApoE,SLCO1B1 and CYP2C19 gene polymorphisms in 202 individuals with dyslipidemia was analyzed to obtain individualized medication information,which provides data-driven support for individualized medication use and can guide individualized,accurate and safe medication use.